LAMEA Anticoagulant Reversal Drugs Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), By Product Type (Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Anticoagulant Reversal Drugs Market
Market Report Description
The Latin America, Middle East and Africa Anticoagulant Reversal Drugs Market would witness market growth of 14.3% CAGR during the forecast period (2021-2027).
The burden of cardiac arrhythmias has increased in Africa. Atrial fibrillation (AF) is the common type of arrhythmia and it is responsible for significant morbidity and mortality. Until recently, there were limited available treatment options with the support treatment of vitamin K antagonists (VKAs). The introduction of new anticoagulants has brought new hope to arrhythmia patients.
The risk factors, complications, and management of atrial fibrillation (AF) in sub-Saharan Africa need to be managed. The use of anticoagulation for the prevention of stroke is one of the therapeutic strategies. AF is sometimes associated with excessive bleeding in severe conditions and it requires the anticoagulent reversal drug. Thus, the demand for anticoagulation reversal drugs has increased in the sub-African region.
The geriatric population is directly proportional with the rising cases of blood-related disorders that require anticoagulation, thus boosting the demand for anticoagulants. In the past few years, clinicians have been supported by the increased availability of reversal agents. The advent and active research in developing targeted therapies such as idarucizumab have offered better treatment management for anticoagulant-associated bleeding and other periprocedural reversal.
Current trials evaluating aripazine and andexanet alfa will continue to widen the available regimen of effective agent-specific therapy. The reversal of a patient’s anticoagulation status solely depends on the health condition of the patient. The benefits of anticoagulant reversal drugs against the risks of thrombosis require a good understanding of anticoagulant intake by the patients and their respective antidotes.
The Hospital Pharmacy market dominated the UAE Anticoagulant Reversal Drugs Market by Distribution Channel in 2020, thereby, achieving a market value of $11.2 million by 2027. The Retail Pharmacy market is exhibiting a CAGR of 13.5% during (2021-2027). Additionally, The Online Pharmacy market is expected to witness highest CAGR of 15.4% during (2021-2027).
Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Product Type
- Andexanet Alfa
- Prothrombin Complex Concentrates
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Boehringer Ingelheim International GmbH
- CSL Limited
- Bausch Health Companies, Inc.
- Octapharma AG
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
- Dr. Reddy’s Laboratories Ltd.
- AMAG Pharmaceuticals, Inc. (Covis Pharma)
- Alps Pharmaceutical Ind. Co., Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free